PT837672E - Preparacoes e metodos para o tratamento de doencas mediadas por celulas t - Google Patents

Preparacoes e metodos para o tratamento de doencas mediadas por celulas t

Info

Publication number
PT837672E
PT837672E PT96924371T PT96924371T PT837672E PT 837672 E PT837672 E PT 837672E PT 96924371 T PT96924371 T PT 96924371T PT 96924371 T PT96924371 T PT 96924371T PT 837672 E PT837672 E PT 837672E
Authority
PT
Portugal
Prior art keywords
cells
treatment
preparations
methods
diseases mediated
Prior art date
Application number
PT96924371T
Other languages
English (en)
Inventor
Meir Shinitzky
Irun R Cohen
Dana Elias
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of PT837672E publication Critical patent/PT837672E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
PT96924371T 1995-07-05 1996-07-02 Preparacoes e metodos para o tratamento de doencas mediadas por celulas t PT837672E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number Publication Date
PT837672E true PT837672E (pt) 2004-03-31

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96924371T PT837672E (pt) 1995-07-05 1996-07-02 Preparacoes e metodos para o tratamento de doencas mediadas por celulas t

Country Status (22)

Country Link
EP (1) EP0837672B9 (pt)
JP (2) JP4357595B2 (pt)
KR (1) KR100435040B1 (pt)
CN (1) CN1102382C (pt)
AT (1) ATE254451T1 (pt)
AU (1) AU714970B2 (pt)
CA (1) CA2226013C (pt)
CZ (1) CZ298A3 (pt)
DE (1) DE69630787T2 (pt)
DK (1) DK0837672T3 (pt)
ES (1) ES2211963T3 (pt)
HR (1) HRP960315A2 (pt)
HU (1) HU223081B1 (pt)
IL (2) IL114458A0 (pt)
MX (1) MX9800190A (pt)
NO (1) NO320363B1 (pt)
PT (1) PT837672E (pt)
SI (1) SI0837672T1 (pt)
UY (1) UY24275A1 (pt)
WO (1) WO1997002016A1 (pt)
YU (1) YU40796A (pt)
ZA (1) ZA965666B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP1575526B1 (en) 2002-05-21 2012-06-06 Irun R. Cohen Dna vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
CA2547079A1 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
CN101316610A (zh) 2005-09-22 2008-12-03 艾润·R·科恩 T细胞受体恒定区的免疫原性片段及其衍生的肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients

Also Published As

Publication number Publication date
HUP9802834A2 (hu) 1999-03-29
DE69630787D1 (de) 2003-12-24
SI0837672T1 (en) 2004-04-30
HU223081B1 (hu) 2004-03-29
NO980013L (no) 1998-02-19
IL114458A0 (en) 1995-11-27
ATE254451T1 (de) 2003-12-15
HUP9802834A3 (en) 2001-08-28
EP0837672A4 (en) 1999-01-27
AU6484496A (en) 1997-02-05
AU714970B2 (en) 2000-01-13
CN1193907A (zh) 1998-09-23
MX9800190A (es) 1998-04-30
YU40796A (sh) 1998-11-05
HRP960315A2 (en) 1998-02-28
IL122755A0 (en) 1998-08-16
DE69630787T2 (de) 2004-10-07
CN1102382C (zh) 2003-03-05
NO980013D0 (no) 1998-01-02
CZ298A3 (cs) 1998-06-17
ES2211963T3 (es) 2004-07-16
CA2226013A1 (en) 1997-01-23
EP0837672B9 (en) 2005-06-15
EP0837672B1 (en) 2003-11-19
UY24275A1 (es) 2000-12-29
JP4357595B2 (ja) 2009-11-04
WO1997002016A1 (en) 1997-01-23
JP2009242412A (ja) 2009-10-22
IL122755A (en) 2004-07-25
KR100435040B1 (ko) 2004-08-18
KR19990028738A (ko) 1999-04-15
DK0837672T3 (da) 2004-03-22
JPH11508899A (ja) 1999-08-03
EP0837672A1 (en) 1998-04-29
ZA965666B (en) 1997-01-27
CA2226013C (en) 2012-09-18
NO320363B1 (no) 2005-11-28

Similar Documents

Publication Publication Date Title
Maizels et al. Helminths in the hygiene hypothesis: sooner or later?
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
Zourbas et al. Localization of pro-inflammatory (IL-12, IL-15) and anti-inflammatory (IL-11, IL-13) cytokines at the foetomaternal interface during murine pregnancy
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
CY1108397T1 (el) Αντι-ccr4 αντισωμα και θραυσμα αυτου
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
Matisz et al. Suppression of colitis by adoptive transfer of helminth antigen-treated dendritic cells requires interleukin-4 receptor-α signaling
PT837672E (pt) Preparacoes e metodos para o tratamento de doencas mediadas por celulas t
Rodriguez-Pinto et al. CD4 T cell activation by B cells in human Leishmania (Viannia) infection
Hart et al. More than effects in skin: ultraviolet radiation-induced changes in immune cells in human blood
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
Xu et al. Host defenses in skin
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ES2151544T3 (es) Metodos para la deteccion y el tratamiento de individuos con celulas anormales que expresan antigenos peptidos hla-a2/tirosinasa.
UY27662A1 (es) Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny.
Fernandes et al. Monocyte subsets in schistosomiasis patients with periportal fibrosis
PT782630E (pt) Gene da doenca poliquistica do rim
AR027694A1 (es) Uso de la proteina mia para el tratamiento de enfermedades autoinmunes
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
김도영 Role of regulatory T cells in imiquimod-induced psoriasiform dermatitis model
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.